STUDY QUESTION: What are the in vivo and in vitro actions of kisspeptin-54 on the expression of genes involved in ovarian reproductive function, steroidogenesis and ovarian hyperstimulation syndrome (OHSS) in granulosa lutein (GL) cells when compared with traditional triggers of oocyte maturation?
Introduction
Infertility is estimated to affect one in seven couples and the number of couples receiving fertility treatment is increasing each year (HFEA, 2014) . The most dangerous complication of ART is ovarian hyperstimulation syndrome (OHSS), which can cause ovarian enlargement, ascites, hydrothorax, renal failure, acute respiratory distress syndrome, and can even be life-threatening (Golan et al., 1989; Whelan and Vlahos, 2000) . Severe OHSS occurs in~2-9% of cycles and moderate OHSS in a further 10-16% (HFEA, 2014; Toftager et al., 2016) . Moreover, the risk of severe OHSS is further increased in women with polycystic ovaries (PCO) tõ 12-15% (Lee et al., 2008; Swanton et al., 2010; Jacob et al., 2016) . hCG has traditionally been used to trigger oocyte maturation, but due to a prolonged duration of action on ovarian LH/hCG receptor, its use can lead to OHSS (Elchalal and Schenker, 1997; Rozenberg, 2002a, 2002b) . GnRH agonists (GnRHa) have a shorter duration of action than hCG, and thus are associated with a lower risk of inducing OHSS (Babayof et al., 2006; Corbett et al., 2014; Melo et al., 2009) . However, GnRHa are often used as second line agents due to concerns regarding implantation rates (Griesinger et al., 2006; Youssef et al., 2014) . Kisspeptin is a recently discovered neuropeptide that is obligate for puberty and reproduction. It regulates the hypothalamo-pituitary-gonadal (HPG) axis by acting on kisspeptin receptors (KISS1R) on GnRH neurons to stimulate GnRH, and consequently gonadotropin release (Seminara et al., 2003; de Roux et al., 2003; Kirilov et al., 2013) . We have recently demonstrated that Kisspeptin-54 triggers oocyte maturation in a study of 60 women at high risk of OHSS (Abbara et al., 2015) . Across all doses tested, kisspeptin-54 resulted in oocyte maturation in 95% of patients with biochemical pregnancy, clinical pregnancy, and live birth rates per transfer of 63, 53 and 45%, respectively, with no clinically significant OHSS.
Several studies have compared alterations in gene expression, gonadotropin levels, vascular endothelial markers and growth factor profiles in serum, follicular fluid and granulosa lutein (GL) cells between hCG and GnRH agonist triggered IVF protocols (Doldi et al., 1997; Wang et al., 2002; Villasante et al., 2008; Cerrillo et al., 2009 Cerrillo et al., , 2011 Haas et al., 2014; Miller et al., 2016) . Levels of vascular endothelial growth factor (VEGF) (Doldi et al., 1997; Wang et al., 2002; Cerrillo et al., 2009 Cerrillo et al., , 2011 , Cadherin 5 (CDH5) (Villasante et al., 2008) and platelet endothelial-derived factor (PEDF, also known as SERPINF1) (Miller et al., 2016) are putative markers of OHSS and have been shown to be different between hCG and GnRHa triggered cycles (Cerrillo et al., 2009 (Cerrillo et al., , 2011 Haas et al., 2014) . Microarray analysis of cumulus and mural granulosa cells has shown differences in genes involved in lipid and steroid metabolism, and platelet degranulation (Borgbo et al., 2013) . In addition, Haas et al. (2014) studied the differential effects on gene expression in granulosa cells from women who were triggered with hCG or GnRH agonists. They found that granulosa cells from women who had received GnRHa as a trigger had lower expression of genes related to steroidogenesis and gonadotropin regulation (CYP19A1, CYP11A1, 3BHSD, FSHR, inhibin B and amphiregulin). These changes may reflect the different hormonal profiles and likelihood to induce OHSS between the two triggers.
It is known that both kisspeptin (KISS1) and its G-protein-coupled kisspeptin receptor (KISS1R) are expressed in the human ovary (Cejudo Roman et al., 2012) . However, the direct effects of kisspeptin on the ovary have yet to be fully elucidated. No study has examined the effects of triggering oocyte maturation using kisspeptin-54 on expression of genes involved in OHSS and steroidogenesis in the ovary. Thus, the aims of this study were: (i) To assess the in vivo effects of kisspeptin-54 on gene expression markers of ovarian function/steroidogenesis and OHSS in human GL cells, in comparison to traditional triggers of oocyte maturation (hCG, GnRHa). (ii) To determine whether the effects of kisspeptin-54 treatment are via the HPG axis and/or via direct actions on human GL cells. This is the first study to address the impact of triggering oocyte maturation with kisspeptin-54 on human granulosa cell function.
Materials and Methods

Study approval
As previously described in Abbara et al. (2015) , the kisspeptin study was carried out in the IVF Unit at Hammersmith Hospital under a license from the United Kingdom Human Fertilization and Embryology Authority. Written informed consent was obtained from all subjects prior to inclusion in the study. Approval of this study as a Clinical Trial of an Investigative Medicinal Product was granted by the Medicines and Healthcare Products Regulatory Agency, UK. The study was registered on the National Institutes of Health Clinical Trials database (ClinicalTrials. gov NCT01667406). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was also obtained from all subjects prior to collection of GL cells. The Hammersmith and Queen Charlotte's Research Ethics Committee, London, UK, approved both studies (Reference 08/H0707/152, 10/H0707/2).
Study participants
Forty-eight women undergoing IVF treatment for infertility at Hammersmith hospital consented to use of kisspeptin-54 maturation trigger use and/or granulosa cell collection and were included in the study. Twelve women received hCG, 12 received GnRH agonist and 24 received kisspeptin-54 to trigger oocyte maturation. In the kisspeptin-54 group, 12 received one injection of kisseptin-54 (9.6 nmol/kg) and 12 received two injections of kisspeptin-54 at a 10 h interval (9.6 nmol/kg × 2). As per hospital protocol, hCG was the standard treatment used for oocyte maturation. GnRH agonist treatment was reserved for women with a high baseline risk of OHSS, i.e. those with PCOS or high antral follicle count (AFC). Kisspeptin-54 was also given to women with a high risk of OHSS and the inclusion criteria for the kisspeptin-54 trial have been detailed previously (Abbara et al., 2015) . These criteria included: serum AMH ≥ 40 pmol/L (≥5.6 ng/mL) or total AFC ≥ 23, age 18-34 years, early follicular phase serum FSH ≤ 12 mIU/mL and both ovaries intact. Exclusion criteria were moderate/severe endometriosis or poor response to more than one previous cycle of IVF treatment.
The indications for IVF were infertility for PCOS, tubal problems, male factor infertility or infertility of unknown cause. In addition, these women met the NHS criteria for assisted reproduction, i.e. had a body mass index <30 kg/m 2 , were aged ≤40 years and were non-smokers. PCO were defined sonographically as the presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter and/or increased ovarian volume (>10 mL). Polycystic ovary syndrome (PCOS) was defined according to the Rotterdam diagnostic criteria (i.e. two or more of the following: oligoor anovulation, hyperandrogenism and PCO). Four women had ovaries that contained more than 12 follicles, but without an increase in stroma and without clinical or biochemical evidence of PCOS.
Study outcomes
We measured gene expression of factors involved in ovarian reproductive function and steroidogenesis; LHCGR, FSHR, CYP19A1, cholesterol sidechain cleavage enzyme (CYP11A1), 3BHSD2, STAR, kisspeptin (KISS1), kisspeptin receptor (KISS1R), ESR1, ESR2. We also measured gene expression of putative markers of OHSS; vascular endothelial growth factor (VEGFA), cadherin 5 (CDH5), Serpin Family F Member 1 (SERPINF1, also known as PEDF, pigment endothelial-derived factor) and growth factors involved in regulating oocyte growth; amphiregulin (AREG) epiregulin (EREG), inhibin A and B (INHBA, INHBB). These were measured from GL cells extracted at the time of oocyte retrieval and from cells cultured in vitro and treated with either hCG or kisspeptin-54. For in vivo treated samples, a separate analysis compared those women who received one or two kisspeptin-54 injections. Women who received hCG and were either 'control' or PCO were also analyzed separately to remove the confounding effect of PCO. Intracellular signaling responses phospho-ERK, phospho-AKT and calcium signal generation in response to in vitro kisspeptin-54 treatment were also measured.
Ovarian stimulation protocol
Participants who did not receive kisspeptin-54 underwent cycles of IVF under two distinct stimulation protocols: Long Day 21 (LD-21) or antagonist. In a LD-21 cycle gonadotropin-releasing hormone agonist (Buserelin 0.5 mg, Sanofi, Guildford UK) was used to suppress the pituitary production of gonadotropins for two weeks starting from Day 21 of the menstrual cycle. Ovarian suppression was confirmed with an ultrasound scan and stimulation was started using recombinant follicular stimulating hormone.
FSH dose varies based on ovarian reserve and can range between 112.5 and 450 units. hCG 5000 units was administered once at least three follicles reached ≥18 mm in diameter; oocyte retrieval followed 36 h later. The antagonist cycle was more commonly used in PCO cases to reduce the risk of OHSS. Ovarian stimulation was started on the second day of the menstrual cycle, a GnRH antagonist (Cetrorelix or Ganirelix 0.25 mg daily, Merck Serono, Feltham, UK) was used from Day 5 to prevent a premature LH surge. hCG (Ovitrelle and Pregnyl, Merck Serono) or a GnRHa (Buserelin 2 mg) was administered when at least three follicles reached ≥18 mm in diameter, and transvaginal oocyte retrieval was carried out 36 h thereafter. The IVF protocol for the kisspeptin-54 (Bachem, Bubendorf, Switzerland) trial has previously been described in detail, see Abbara et al. (2015) .
Granulosa-lutein cell collection and isolation
Follicular fluid was aspirated and pooled from follicles of individual women during the retrieval of oocytes for IVF/ICSI. The GL cells were extracted by centrifugation at 1000 rpm for 5 min to separate the fluid from cells, as previously described (Rice et al., 2005) . The cell pellets were resuspended in M199 (Thermo fisher Scientific, Waltham, MA USA) and layered onto Percoll (GE healthcare, Chicago, USA) gradient (Rice et al., 2005) and then centrifuged at 1600 rpm for 30 min to separate red blood cells. The GL cells at the interface were collected and washed with Dulbecco's phosphate buffered saline (DPBS, Thermo Fisher Scientific). The cells were then either frozen and stored at −80°C or RNA was extracted immediately.
Quantitative real-time PCR
RNA was extracted from cells using RNeasy ® plus Mini Kit (Qiagen Inc., CA, USA) according to manufacturer's instructions. The RNA samples were stored at −80°C until all samples were collected. The quantity, quality and integrity of samples was analysed using Agilent Technologies 2200 Tapestation (Agilent, CA, USA). Samples with an RNA integrity number >5 were included. RNA was reverse transcribed into cDNA using Invitrogen superscript IV First Strand synthesis system. Quantitative, real-time PCR (RT-qPCR) was carried out on 384 well plates using POWER SYBR Green (Applied Biosystems, CA, USA) according to the manufacturer's instructions on an Applied Biosystems 7900 HT instrument. Primer sequences are listed in Supplementary Table S1 . The relative mRNA expression of each gene was calculated using the housekeeping genes β-actin and β2-microglobulin as reference genes. A geNorm kit (Primer Design, Chandler's Ford, UK) was used to select the best candidate reference genes. Placental cDNA was used as positive control tissue for KISS1 and KISS1R analysis.
Granulosa cell culture and in vitro treatment with hCG/kisspeptin GL cells isolated from pooled follicular fluid were cultured in 6-well plates (1 × 10 6 cells per well) in serum-free culture medium (supplemented DMEM/F12 Ham mixture, Thermo Fisher Scientific). The medium was completely refreshed every 48 hours. After 72 h in culture, cells were treated with either 1 μM kisspeptin-54 dissolved in 0.9% (w/v) saline or 10 nM hCG (Harbor UCLA Medical Centre, USA) dissolved in PBS for 48 h, to mimic the in vivo oocyte maturation trigger protocol. After this 36 h period, cells were lysed, collected for RNA extraction and qPCR, as described above. The cells were cultured for 72 h prior to treatment as we have found that the number and activity of gonadotropin receptors (and the response of steroidogenic enzymes to gonadotropins) increase with time in culture ( Supplementary Fig. S1 ), despite having been subjected to high doses of FSH and/or hCG in vivo. GL cells were also cultured for 24 h in similar conditions, then treated with 0.1, 1 or 10 μM kisspeptin-54 for 0, 5, 10, 15, 30, 60 min, with or without LH 10 nM (Harbor UCLA Medical Centre, USA). After treatment, the cells were harvested and rinsed with PBS and then lysed with 40 μL RIPA buffer per well (Thermo Fisher Scientific). Cell lysates were centrifuged at 12 000 g for 10 min and the supernatant removed. Protein was quantified using the BCA (bicinchoninic acid) Protein Assay Kit (Thermo Fisher Scientific). Each sample was denatured at 70°C for 10 min, loaded to a Bolt 4-12% Bis-Tris Plus Gels (Invitrogen, CA, USA), and then transferred to a polyvinylidene difluoride membrane (Thermo Fisher Scientific). The membranes were washed three times for 15 min in TBST (Tris-buffered saline, 0.1% Tween 20) and blocked with 5% BSA for 1 h. Membranes were incubated with primary antibodies (phospho-p42/44 MAPK, Phospho-Akt (Ser473) Antibody, Cell Signaling Technology, MA, USA) at 4°C overnight. Membranes were then incubated with horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (Thermo Fisher Scientific) for 1 hr at room temperature. The immunoblots were visualized by enhanced chemiluminescence detection (Thermo Fisher Scientific) and quantified by densitometric scanning. The band densities were normalized with that of GAPDH.
GL cells cultured for 24 h as described above and were also pretreated with a Fluo-4 calcium indicator dye (Invitrogen) for 1 h to detect calcium flux in response to ligand administration at live imaging, then kisspeptin-54 10 μM was administered and cell fluorescence emission recorded, as per manufacturer's instructions.
Statistical analysis
One-way ANOVA or Students t-test was used to compare means between three or two parametric groups. Mann Whitney U and Kruskal Wallis tests were used for comparing medians of nonparametric data. A Tukey's correction for multiple comparisons was carried out. Pearson correlation coefficient was used to correlate gene expression results with FSH dose, age and AFC. A power calculation was used to determine that 12 samples would be required for in vitro treatment with kisspeptin-54 based on the in vivo gene expression data (beta 80%; alpha 5%). A P-value of <0.05 was considered to indicate statistically significance. Statistical analysis was performed using GraphPad, Prism, version 6.
Results
Baseline characteristics
Women who received kisspeptin-54 to trigger oocyte maturation were significantly younger than those who received hCG or GnRH agonist (29 versus 33 years, P = 0.001) ( Table I) . Mean body mass index was similar in the three groups. Baseline AFC was lower in women who were triggered with hCG than with GnRH agonist or kisspeptin, as half of this group did not have PCO/PCOS (P < 0.001). AFC was not significantly different between the GnRH agonist and kisspeptin groups. The mean dose of recombinant FSH received as part of IVF stimulation protocol was higher in women without PCOS who received hCG compared to those who had PCOS or had a GnRH agonist (P = 0.01) or kisspeptin (P = 0.002) trigger. All the women in the GnRH agonist or kisspeptin groups had PCO (or had multiple ovarian follicles without increased stroma). Half of the women in the hCG group had PCO/PCOS and half had IVF for male factor infertility, tubal problems or unexplained infertility.
Gene expression-gonadotropin receptors/kisspeptin receptor GL cells from women who had received kisspeptin-54 had a 14-fold (P < 0.001) and 8-fold (P < 0.01) higher expression of FSH receptor gene than GL cells from women who had received hCG or GnRH agonist, respectively (Fig. 1) . The mean rise in serum FSH level 4 h after administration of kisspeptin-54 was 2.4 ± 1.8 mIU/ml. Given that women in the kisspeptin-54 group were more likely to have PCO and higher AFCs and that FSHR expression is known to be higher in GL cells from women with PCOS, we correlated FSHR to AFC to show that the higher FSHR expression was not confounded (Fig. 1B) .
GL cells from women who had received kisspeptin-54 had a 2-fold (NS) and 2.5-fold (P < 0.05) higher expression of LH receptor gene than GL cells from women who had received hCG or GnRH agonist, respectively (Fig. 1D) . LHCGR expression was significantly higher in women who received two injections of kisspeptin-54 10 h apart when compared with women who had received only one (P < 0.05). The mean rise in serum LH level 4 h after administration of kisspeptin was 55.4 ± 30.7 mIU/ml (Fig. 1C) . There was no correlation between LHCGR expression and baseline AFC. Women with a higher peak levels of serum LH appeared to have lower GL cell LHCGR gene expression and vice versa (see Fig. 1F , NS). Baseline (pretreatment) serum concentrations of FSH were all within the normal, premenopausal range and there was no (Fig. 1G) . Excluding the control women from the hCG group did not change any of the above results.
Gene expression-ovarian steroidogenic enzymes CYP19A1 (aromatase) expression was 3.6-fold (P < 0.05) and 4.5-fold (P < 0.05) higher in GL cells from women who had received kisspeptin-54 than hCG or GnRHa, respectively (Fig. 2) . CYP11A1 expression was similar amongst the three groups. Expression of STAR was 3.4-fold higher (P < 0.01) and 1.8-fold higher (P < 0.05) in women who had received Figure 1 Gene expression of gonadotropin and kisspeptin receptor genes in human granulosa lutein (GL) cells after oocyte maturation with hCG, GnRH agonist or Kisspeptin-54, and correlation of gene expression with antral follicle count (AFC) and serum gonadotropins. hCG group (n = 12), GnRH agonist (GnRHa) (n = 12) or Kisspeptin-54 (Kiss) (n = 24). Kisspeptin-54 (9.6 nmol/kg) was given as one or two doses at a 10 hr interval and these groups are delineated separately. The hCG group were analyzed with and without the control (non- Luteinizing hormone receptor gene expression (LHCGR) is higher in GL cells from women who received kisspeptin-54 as maturation trigger than GnRH agonist (P < 0.05) but is not higher than hCG. (E) LHCGR gene expression is higher in GL cells from women who received two kisspeptin-54 injections to trigger maturation (2 × 9.6 nmol/kg 10 h apart, n = 12) than women who received one injection (9.6 nmol/kg), P = 0.038. (F) Correlating LHCGR gene expression with changes in serum LH after kisspeptin injection. Women who had a rise in serum LH of >50 mIU/ml 4 h post trigger had a non-significantly lower gene expression of LHR than women who had a rise in serum LH of <50 mIU/ml 4 h post trigger. (G) kisspeptin receptor gene (KISS1R) expression was similar in granulosa cells from women who received hCG, GnRH agonist or kisspeptin to trigger oocyte maturation. Figure 2 Gene expression of genes involved in ovarian steroidogenesis in human granulosa lutein (GL) cells after oocyte maturation with hCG, GnRH agonist or kisspeptin-54. hCG group (n = 12), GnRH agonist (GnRHa) (n = 12) or Kisspeptin-54 (Kiss) (n = 24). Kisspeptin-54 (9.6 nmol/kg) was given as one or two doses at a 10hr interval and these groups are delineated separately. The hCG group were analyzed with and without the control kisspeptin-54 than PCO women in hCG group and GnRHa group, respectively. STAR expression was higher in those who had received two injections of kisspeptin-54 to trigger oocyte maturation than those who had received one (P = 0.04). 3β-Hydroxysteroid dehydrogenase 2 (HSD3B2) expression was 7.5-(P < 0.01) and 2.5-fold higher (P < 0.05) in kisspeptin group than those who had received hCG (PCO only) and GnRHa, respectively. ESR1 and ESR2 both showed 3-fold higher expression in cells from kisspeptin treated than GnRHa treated women. Inhibin A gene expression was 2.5-fold higher from GL cells from women who had received kisspeptin-54 than hCG or GnRHa (P < 0.01). Inhibin A gene expression did not relate to pretreatment AFC. Inhibin B expression was similar amongst the three groups.
Gene expression-markers of OHSS
There was no significant difference, amongst the three maturation triggers, between the gene expression of genes that are involved in vascular permeability and integrity; VEGFA, SERPINF1 and CHD5, nor in expression of growth factors amphiregulin and epiregulin, which have been previously shown to be potential markers of OHSS (Fig. 3) .
In vitro effects of kisspeptin-54
GL cells (n = 12) cultured and treated in vitro with kisspeptin-54 alone for 48 h did not elicit the same changes in gene expression as those in vivo. Gene expression of LHCGR, FSHR, CYP19A1, CYP11A1, HSD3B2, STAR, KISS1R, ESR1, ESR2, VEGF, SERPINF1, AREG, EREG, INHBA, INHBB were similar in kisspeptin-54 treated GL cells compared to untreated cells ( Supplementary Fig. S2 ). GL cells treated with hCG had significantly higher expression of LHCGR, STAR, CYP11A1, INHBA and lower expression of INHBB and ESR2 compared to untreated cells or cells treated with kisspeptin-54 ( Supplementary Fig. S2 ). GL cells cultured and treated with kisspeptin-54 did not stimulate production of phospho-ERK, phospho-AKT or elicit an intracellular calcium signaling response.
Discussion
To our knowledge this is the first study to examine both in vivo and in vitro effects of kisspeptin-54 on human ovarian GL cells. The data contribute to the current literature elucidating the direct and indirect ovarian effects of kisspeptin-54. As the therapeutic role for kisspeptin continues to grow, it is important that its mechanism of action and effects on target organs are comprehensively examined. We have demonstrated that kisspeptin, when given as a trigger for oocyte maturation in IVF, alters GL gene expression considerably when compared to traditional triggers of maturation. It results in a higher expression of FSH and LH receptor, and higher expression of genes involved in ovarian steroid production and action; steroidogenic acute regulatory protein, 3β-hydroxysteroid dehydrogenase, aromatase, inhibin A, estrogen receptors 1 and 2. These changes occur in the absence of changes in the expression of kisspeptin receptor (and with no evidence of kisspeptin gene expression in these cells). These alterations in gene Figure 3 Gene expression of potential markers of ovarian hyperstimulation in human luteinized granulosa (GL) cells after oocyte maturation with hCG, GnRH agonist or kisspeptin-54. hCG group (n = 12), GnRH agonist (GnRHa) (n = 12) or Kisspeptin-54 (Kiss) (n = 24). Kisspeptin-54 (9.6 nmol/ kg) was given as one or two doses at a 10 h interval and these groups are delineated separately. The hCG group were analyzed with and without the control (non-polycystic ovary (PCO) women). Data are presented as the mean + SEM and scattergram of individual gene expression values. There is no significant difference between gene expression in the three groups for any of the markers (A) vascular endothelial growth factor VEGFA, (B) Serpin Family F Member 1 (SERPINF1), (C) Cadherin-5 (CHD5), (D) amphiregulin (AREG) and (E) epiregulin (EREG).
expression are not seen in GL cells treated in vitro with kisspeptin-54 alone and are therefore more consistent with an indirect effect of kisspeptin-induced changes in gonadotropin secretion. GL cells from women who received kisspeptin-54 do not have changes in markers of ovarian hyperstimulation VEGF, PEDF, Cadherin 5, amphiregulin and epiregulin, despite these women having a high baseline risk of OHSS. Kisspeptin-54, the major circulating isoform of kisspeptin in humans, has been shown to effectively trigger egg maturation in women undergoing IVF treatment (Jayasena et al., 2014) , with no clinically significant OHSS (Abbara et al., 2015) . It is known that hypothalamic kisspeptin affects ovarian activity indirectly via stimulating gonadotropin secretion. Both kisspeptin and G-protein-coupled kisspeptin receptor (KISS1R) are expressed in the human ovary (Gaytan et al., 2009) . In vitro treatment of cultured rat luteal cells with kisspeptin-10 increased basal and hCGinduced progesterone levels but not estradiol production, with concomitant increases in levels of key steroidogenic enzymes STAR, CYP11A, and HSD3B2 and increased the phosphorylation of Erk1/2 mitogen-activated protein kinase (Gaytan et al., 2009) . A study in pre-ovulatory chicken granulosa cells treated with kisspeptin-10 found an increase in progesterone secretion and steroidogenic gene expression (Xiao et al., 2011) . These studies suggest a direct effect of kisspeptin-10, however, evidence for this direct effect is contradicted by the observation that mice with GnRH neuron-specific deletions of KISS1R are infertile and fail to go through puberty (Kirilov et al., 2013) . They subsequently knocked in the KISS1R to the GnRH neurons to the model, resulting restoration of normal pubertal onset and fertility suggesting that it is the GnRH neuron that is the key site of kisspeptin signaling.
Kisspeptin-54 administration stimulates a rise in both LH and FSH but with a relatively greater effect on LH, a similar pattern to what has been shown previously (Narayanaswamy et al., 2016) . Doses of GnRH agonist used in current IVF treatment are likely to be at the high end of the dose-response curve, resulting in a higher amplitude of FSH and LH secretion than observed with kisspeptin-54 (Vuong et al., 2016) . Kisspeptin stimulates GnRH neurons to secrete endogenous GnRH, whereas a GnRH agonist can also stimulate GnRH receptors, which are not contiguous with GnRH neurons resulting in higher amplitude of gonadotropin secretion at equimolar doses (Jayasena et al., 2014) . The lower amplitude of gonadotropin secretion with kisspeptin-54, compared with GnRHa or hCG may explain the significantly higher expression of FSHR and LHCGR (Gonen et al., 1990; Fauser et al., 2002; Decleer et al., 2014) . In fact, the excursions in serum gonadotropins are closer to that of the peri-ovulatory changes in gonadotropins in the natural unstimulated cycle (Direito et al., 2013) . FSH and LH have been shown to downregulate expression of their own receptors (Hirsh et al., 2005; Xu et al., 2011; Jeppesen et al., 2012) . However, a study by Rimon et al. (2004) showed that in luteinised granulosa cells, LH administration resulted in increased density of LHCGR transcripts, although these cells responded inefficiently to gonadotropin stimulation. The rise in FSH receptor expression is not related to dose of recombinant FSH administration during the stimulation phase of the IVF cycles, as women triggered with kisspeptin-54 or GnRHa received similar doses of recombinant FSH, and less than those who received hCG. It also did not correlate with the higher AFC that the women in the kisspeptin-54 group had, as PCOS is known to be associated with increased GL cell FSHR expression (Catteau-Jonard et al., 2008) .
The relatively high FSHR gene expression after kisspeptin-54 administration and subsequent augmentation of downstream signaling, could in turn augment enzymes involved in progesterone synthesis (STAR, HSD3B2), androgen synthesis (HSD3B2) and aromatization of androgens to estrogens (CYP19A1). Estradiol has been shown to upregulate expression of its own receptor and the increased production of estradiol may be an explanation for the increase in ER gene expression that we observe here (Barton and Shapiro, 1988; Ing and Tornesi, 1997) . Enhanced production and/or action may in turn contribute to upregulation of FSH and LH receptor expression (Dankbar et al., 1995) . We also saw a higher expression of inhibin A in granulosa cells from kisspeptin treated women than hCG or GnRH agonists. Inhibins are produced by granulosa cells and negatively feedback to inhibit FSH secretion by the pituitary. Inhibin A is the predominant form produced during the late follicular phase and it has been shown previously that inhibin A, in addition to its feedback on the pituitary, can act directly on the ovaries and can suppress FSHR gene expression in granulosa cells (Lu et al., 2009) . It is possible that the upregulation of inhibin A may be a compensatory response to the higher FSHR expression.
There was no significant difference seen in markers of potential OHSS between the three groups, despite reports in the literature showing that triggering maturation with hCG results in an increased likelihood of OHSS, and studies showing alterations in these markers in hCG treated women (Cerrillo et al., 2009 (Cerrillo et al., , 2011 Haas et al., 2014; Borgbo et al., 2013) . One possible explanation for this is that the hCG group in this study had lower baseline risk of OHSS with a lower baseline AFC and older age, and hence also did not have any evidence of changes associated with OHSS. The kisspeptin trial specifically targeted women at high risk of OHSS. In addition, we know that no women in this study actually developed clinically significant OHSS. Recently it has been shown in a rat OHSS model that kisspeptin-10 prevented the increased vascular permeability of OHSS probably by the activation of KISS1R and the inhibition of VEGF (Zhai et al., 2017) . Thus, kisspeptin triggering could therefore additionally prevent OHSS through a direct ovarian action, thus indicating as to why these women at high risk of OHSS did not have higher VEGF expression. In addition, although identical quantities of RNA were used and gene expression was normalized to two housekeeper genes, the analysis does not account for the potential impact of differing numbers of follicles aspirated from individual women and possible differences in gene expression amongst follicles from a single individual.
We treated GL cells in vitro with kisspeptin-54 or hCG and measured steroidogenic and gonadotropin receptor gene expression. Kisspeptin treatment alone did not alter steroidogenic or gonadotropin receptor gene expression. This is consistent with kisspeptin's action being predominantly at the level of the hypothalamus and pituitary as opposed to direct action at the ovary. Alternatively, kisspeptin may require the presence of other gonadotropins to directly alter steroidogenesis, or perhaps an alternative isoform, e.g. Kiss-10 (Xiao et al., 2011; Peng et al., 2013) may have differing receptor affinity for ovarian KISS1R.
There are several limitations to our study. (i) Nearly all the women in our study had PCO. We have dealt with this confounder by completing the analyses with and without the women with PCOS, to interrogate this as a confounder and found no differences. (ii) For the analysis of in vitro effects of kisspeptin-54, it is important to note that GL cells have already been exposed in vivo to an alternate maturation trigger, which could confound the results. However, we have shown GL cells maintain gonadotropin receptor expression and capacity for steroidogenesis in culture, suggesting that they are still useful for in vitro measurement of steroidogenesis. (iii) As part of the selection process for inclusion in the kisspeptin trial women had to be 34 years of age or younger, as they were pre-selecting women at higher risk of OHSS. Younger women are at higher risk of OHSS and this may have cofounded the data relating to markers of ovarian hyperstimulation. This is the first study to examine the effects of kisspeptin-54, when used as an oocyte maturation trigger for IVF treatment, on granulosa cell gene expression. We have shown that kisspeptin-54 in vivo augments gonadotropin receptor gene expression and steroidogenic enzymes, when compared with traditional oocyte maturation triggers hCG and GnRHa. In addition, we have studied the in vitro effects of kisspeptin-54 on GL cell gene expression and steroidogenesis, overall adding to the limited knowledge base on the direct and indirect effects of kisspeptin in the human ovary. The excursions in serum gonadotropins are closer to that of the physiological menstrual cycle than other triggers and the expression of receptors and steroidogenic enzymes potentially creates an ovarian environment augmented for progesterone synthesis and luteal phase implantation. This mirrors what has been shown in animal models treated with kisspeptin (Gaytan et al., 2009; Xiao et al., 2011) . As the therapeutic uses of kisspeptin continue to expand knowledge of its effects on targets organs are critical. In conclusion, it appears that changes in markers of ovarian steroidogenesis seen in those who had received kisspeptin-54 are related to the altered gonadotropin profile seen with kisspeptin, as opposed to being related to direct ovarian stimulation by kisspeptin.
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